Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
ORGANIZATION
Drug Makers Step Up Self-Inspections for Supply Stability: FPMAJ Survey
The Federation of Pharmaceutical Manufacturers’ Associations of Japan (FPMAJ) on April 7 released the results of a survey on companies’ self-inspections to ensure the stable supply of ethical drugs. The survey — which drew responses from more companies than in…
To read the full story
Related Article
ORGANIZATION
- COVID-19 Vaccination Rates Fall as Out-of-Pocket Costs Rise: Jiji Survey
May 21, 2026
- Awareness of HPV Vaccination for Males Stands at 39.4%: Survey
May 21, 2026
- Pharma Wage Hikes Seen Settling in Low 4% Range Again: UA Zensen Official
May 21, 2026
- Patient Group Pushes Emergency Steps to Address Concerta Supply Imbalances
May 18, 2026
- Labor Group Urges Priority Supply of Petrochemical Products for Drug Manufacturing
May 15, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…